Table 2.
Comparison of drug withdrawals in China and the United States (US)
| Drug | China | US | ||
|---|---|---|---|---|
| Year of marketing | Year of withdrawal | Year of marketing | Year of withdrawal | |
| Phenylpropanolamine | 1984 | 2000 | 1947 | 2000 |
| Aprotinin | 1975 | 2007 | 1993 | 2007 |
| Pergolide mesylate | 1996 | 2007 | 1988 | 2007 |
| Tegaserod | 2003 | 2007 | 2002 | 2007 |
| Fenfluramine | 1984 | 2009 | 1973 | 1997 |
| Sibutramine | 1999 | 2010 | 1997 | 2010 |
| Dextropropoxyphene | 1996 | 2011 | 1957 | 2010 |
| Pemoline | 1983 | 2015 | 1975 | 2005 |
| Chlormezanone | 1996 | 2016 | 1960 | 1996 |
| Phenformin | 1963 | 2016 | 1959 | 1977 |
| Terfenadine | 1989 | 2018 | 1985 | 1997 |
| Furazolidone | 1959 | 2019 | 1958 | 1991 |
| Metamizole | 1953 | 2020 | NA | 1977 |
| Oxyphenbutazone | 1976 | 2020 | 1960 | 1985 |
| Phenolphthalein | 1955 | 2021 | 1902 | 1997 |
Metamizole was withdrawn based on its injection formulation. Tegaserod was first approved for the treatment of IBS-C and chronic idiopathic constipation in the US in 2002 and 2004, respectively, and then withdrawn from the US market in 2007 due to adverse cardiovascular events. Following additional safety data, tegaserod was approved again for use in the US for IBS-C under more restricted labeling in April 2019
NA not available, IBS-C irritable bowel syndrome with constipation, US United States